Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева; 2ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310 yubykov@gmail.com
Список исп. литературыСкрыть список 1. Агамамедова И.Н., Никитина Т.Е. Комбинированная терапия постинсультных депрессий: венлафаксин и когнитивно-поведенческая психотерапия. Мед. совет. 2017; 11: 194–7. / Agamamedova I.N., Nikitina T.E. Kombinirovannaia terapiia postinsul'tnykh depressii: venlafaksin i kognitivno-povedencheskaia psikhoterapiia. Med. sovet. 2017; 11: 194–7. [in Russian] 2. Государственный реестр лекарственных средств. http://www.grls.rosminzdrav.ru/grls.aspx / Gosudarstvennyi reestr lekarstvennykh sredstv. http://www.grls.rosminzdrav.ru/grls.aspx [in Russian]. 3. Мосолов С.Н., Костюкова Е.Г., Городничев А.В. и др. Клиническая эффективность и переносимость препарата венлафаксин (Велаксин) при лечении умеренной и тяжелой депрессии. Современная терапия психических расстройств. 2007; 3: 58–63. / Mosolov S.N., Kostiukova E.G., Gorodnichev A.V. i dr. Klinicheskaia effektivnost' i perenosimost' preparata venlafaksin (Velaksin) pri lechenii umerennoi i tiazheloi depressii. Sovremennaia terapiia psikhicheskikh rasstroistv. 2007; 3: 58–63. [in Russian] 4. Наприенко М.В., Латышева Н.В., Филатова Е.Г. Новые возможности лечения хронической ежедневной головной боли. Журн. неврологии и психиатрии им. C.C.Корсакова. 2010; 110 (9): 33–8. / Naprienko M.V., Latysheva N.V., Filatova E.G. Novye vozmozhnosti lecheniia khronicheskoi ezhednevnoi golovnoi boli. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2010; 110 (9): 33–8. [in Russian] 5. Напрюшкина В.И., Долинская Ю.А., Дума С.Н., Рымар О.Д. Синдром фибромиалгии у пациентки с послеоперационным пангипопитуитаризмом. Клинический случай. Неврология Сибири. 2016; 2: 29–31. / Napriushkina V.I., Dolinskaia Yu.A., Duma S.N., Rymar O.D. Sindrom fibromialgii u patsientki s posleoperatsionnym pangipopituitarizmom. Klinicheskii sluchai. Nevrologiia Sibiri. 2016; 2: 29–31. [in Russian] 6. Рачин А.П., Сергеев А.В. Доказательная фармакоаналитика применения венлафаксина в клинической медицине. Журн. неврологии и психиатрии. 2009; 109 (5): 68–70. / Rachin A.P., Sergeev A.V. Dokazatel'naia farmakoanalitika primeneniia venlafaksina v klinicheskoi meditsine. Zhurn. nevrologii i psikhiatrii. 2009; 109 (5): 68–70. [in Russian] 7. Пантелеева Г.П., Олейчик И.В., Абрамова Л.И., Юматова П.Е. Лечение эндогенных депрессий венлафаксином: клиническое действие, переносимость и персонифицированные показания к назначению. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (1–2): 43–51. / Panteleeva G.P., Oleichik I.V., Abramova L.I., Yumatova P.E. Lechenie endogennykh depressii venlafaksinom: klinicheskoe deistvie, perenosimost' i personifitsirovannye pokazaniia k naznacheniiu. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (1–2): 43–51. [in Russian] 8. Припутневич Д.Н., Куташов В.А., Саблина Л.А. Эффективность венлафаксина при терапии депрессивных расстройств при гипотериозе. Науч.-мед. вестн. Центрального Черноземья. 2015; 59: 90–4. / Priputnevich D.N., Kutashov V.A., Sablina L.A. Effektivnost' venlafaksina pri terapii depressivnykh rasstroistv pri gipoterioze. Nauch.-med. vestn. Tsentral'nogo Chernozem'ia. 2015; 59: 90–4. [in Russian] 9. Мазо Г.Э., Незнанов Н.Г. Терапевтически резистентные депрессии. СПб., 2012. / Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii. SPb., 2012. [in Russian] 10. Быков Ю.В., Беккер Р.А., Резников М.К. Терапевтически резистентные депрессии. Практическое руководство. М.: РИОР: ИНФРА-М., 2013. / Bykov Yu.V., Bekker R.A., Reznikov M.K. Terapevticheski rezistentnye depressii. Prakticheskoe rukovodstvo. M.: RIOR: INFRA-M., 2013. [in Russian] 11. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache 2000; 40 (7): 572–80. 12. Akkaya C, Sivrioglu EY, Akgoz S et al. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Hum Psychopharmacol 2006; 21 (5): 337–45. 13. Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63 (11): 1004–9. 14. Amiri S, Farhang S, Ghoreishizadeh MA et al. Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Hum Psychopharmacol 2012; 27 (1): 76–81. 15. Anggadiredja K, Yamaguchi T, Tanaka H et al. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice. Brain Res 2003; 966 (1): 47–53. 16. Banerjee S, Hellier J, Romeo R et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial – a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess 2013; 17 (7): 1–166. 17. Benazzi F. Urinary retention with venlafaxine-haloperidol combination. Pharmacopsychiatry 1997; 30 (1): 27. 18. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005; 66 (Suppl. 8): 30–40. 19. Bradwejn J, Ahokas A, Stein DJ et al. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352–9. 20. Brubacher JR, Hoffman RS, Lurin MJ. Serotonin syndrome from venlafaxine-tranylcypromine interaction. Vet Hum Toxicol 1996; 38 (5): 358–61. 21. Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 2016; 16 (2): 131–44. 22. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 (2): 312–5. 23. Carminati GG, Gerber F, Darbellay B et al. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder. Prog Neuropsychopharmacol Biol Psychiatry 2016; 65: 85–95. 24. Cunningham LA. Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group. Ann Clin Psychiatr 1997; 9 (3): 157–64. 25. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60 (8): 528–35. 26. Dean L. Venlafaxine Therapy and CYP2D6 Genotype. In: Pratt V, McLeod H, Dean L et al, ed. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–2015. 27. Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23 (6): 568–75. 28. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004; 65 (1): 37–43. 29. Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999; 21 (2): 296–308. 30. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997; 33 (4): 671–6. 31. Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res 2002; 36 (3): 111–8. 32. Fang Y, Yuan C, Xu Y et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 2010; 30 (4): 357–64. 33. Fann JR, Bombardier CH, Richards JS et al. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial. JAMA Psychiatry 2015; 72 (3): 247–58. 34. Feighner J. Efficacy and tolerability of short-term venlafaxine XR therapy for GAD. Results of short-term, double-blind, placebo-controlled trials. Postgrad Med 1999; 106 (Suppl. 6): 10–6. 35. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord 1998; 47 (1–3): 55–62. 36. Ferguson J, Whitaker T, Mangano R et al. Preventing relapse of panic disorder in adult outpatient responders to venlafaxine XR. Presented at Anxiety Disorders Association of America (ADAA); March 17–21; Seattle, Washington, 2005. 37. Gill JS, Jamwal S, Kumar P, Deshmukh R. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation. Pharmacol Rep 2017; 69 (2): 306–13. 38. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol 1997; 17 (1): 66–7. 39. Gorman JM, Kent JM. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J Clin Psychiatry 1999; 60 (Suppl. 4): 33–8. 40. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf 2001; 24 (3): 183–97. 41. Hay PJ, Bacaltchuk J. Bulimia nervosa. BMJ Clin Evid 2008. pii: 1009. 42. Hay PJ, Claudino AM. Bulimia nervosa. BMJ Clin Evid 2010. pii: 1009. 43. Hodgman MJ, Martin TG, Krenzelok EP. Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. Hum Exp Toxicol 1997; 16 (1): 14–7. 44. Holl AK, Wilkinson L, Painold A et al. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010; 25 (1): 46–50. 45. Hollander E, Friedberg J, Wasserman S et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2003; 64 (5): 546–50. 46. Huang X, Li C, Luo YL et al. Efficacy of venlafaxine extended-release monotherapy for first-episode depression with painful physical symptoms. Neuroreport 2013; 8; 24 (7): 364–9. 47. Illescas-Rico R, Páez-Agraz F, Arreola-Chávez F et al. Effectiveness and security of venlafaxine XR in the treatment of major depression. Article in Spanish. Rev Med Inst Mex Seguro Soc 2005; 43 (6): 473–8. 48. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24 (2): 87–96. 49. Kelly MA, Pavlicova M, Glass A et al. Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? Drug Alcohol Depend 2014; 144: 42–6. 50. Kennedy SH, McCann SM, Masellis M et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002; 63 (3): 181–6. 51. Khandker R, Zhang H, Gao B. Patient-reported quality of life and functionality in panic disorder: venlafaxine, paroxetine, and placebo. Paper presented at: Anxiety Disorders Association of America; March 17–21; Seattle, Washington, 2005. 52. Kim TS, Pae CU, Yoon SJ et al. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder. Psychiatry Clin Neurosci 2006; 60 (3): 347–51. 53. Kjernisted K, McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther Clin Risk Manag 2007; 3 (1): 59–69. 54. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37 (6): 435–56. 55. Levin GM, Nelson LA, DeVane CL et al. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir. Psychopharmacol Bull 2001; 35 (2): 62–71. 56. Malhotra S, King KH, Welge JA et al. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 2002; 63 (9): 802–6. 57. McDonald J, Corbeil P, Pourcher E. Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia. Am J Geriatr Pharmacother 2011; 9 (2): 133–7. 58. Mokhber N, Abdollahian E, Soltanifar A et al. Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry 2014; 47 (4–5): 131–40. 59. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004; 7 (2): 193–218. 60. Muth EA, Haskins JT, Moyer JA et al. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 1986; 35 (24): 4493–7. Biochem Pharmacol 1986; 35 (24): 4493–7. 61. Nissen C, Feige B, Nofzinger E et al. Transient narcolepsy-cataplexy syndrome after discontinuation of the antidepressant venlafaxine. J Sleep Res 2005; 14 (2): 207–8. 62. Otton SV, Ball SE, Cheung SW et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41 (2): 149–56. 63. Pae CU, Lim HK, Ajwani N et al. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder. Expert Rev Neurother 2007; 7 (6): 603–15. 64. Park P, Caballero J, Omidian H. Use of serotonin norepinephrine reuptake inhibitors in the treatment of attention-deficit hyperactivity disorder in pediatrics. Ann Pharmacother 2014; 48 (1): 86–92. 65. Pinzani V, Giniès E, Robert L et al. Venlafaxine withdrawal syndrome: report of six cases and review of the literature. Rev Med Interne 2000; 21 (3): 282–4. 66. Pizarro M, Fontenelle LF, Paravidino DC et al. An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder. Expert Opin Pharmacother 2014; 15 (10): 1391–401. 67. Plesnicar BK. Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder. Psychiatr Danub 2010; 22 (3): 413–7. 68. Pollack M, Emilien G, Tzanis E et al. Short-term treatment of panic disorder with venlafaxine XR and paroxetine. Presented at: World Congress of Women’s Mental Health; March 17–20; Washington, DC, 2004. 69. Pollack M, Whitaker T, Mangano R et al. Short-term treatment of panic disorder: a comparison of venlafaxine XR vs paroxetine or placebo. Presented at: Anxiety Disorders Association of America (ADAA); March 17–21; Seattle, Washington, 2005. 70. Pollack MH, Worthington JJ, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32 (4): 667–70. 71. Preve M, Mula M, Cassano GB, Pini S. Venlafaxine in somatopsychic and autopsychic depersonalization. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35 (8): 1808–9. 72. Ramaswami R, Villarreal MD, Pitta DM et al. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015; 152 (2): 231–7. 73. Reeves RR, Mack JE, Beddingfield JJ. Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy 2003; 23 (5): 678–81. 74. Richards JS, Bombardier CH, Wilson CS et al. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial. Arch Phys Med Rehabil 2015; 96 (4): 680–9. 75. Rickels K, Etemad B, Khalid-Khan S et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67 (12): 1274–81. 76. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157 (6): 968–74. 77. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Dis 1999; 56 (2–3): 171–81. 78. Salgado A, Oliveira L, Sierra-Siegert M, Salgado JV. Depersonalization and derealization syndrome: report on a case study and pharmacological management. Rev Bras Psiquiatr 2012; 34 (4): 505–8. 79. Shelton C, Entsuah R, Padmanabhan SK, Vinall PE. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005; 20 (4): 233–8. 80. Shelton RC, Haman KL, Rapaport M et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 2006; 67 (11): 1674–81. 81. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60 (1): 22–8. 82. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004; 38 (3): 249–57. 83. Singh P, Sharma B. Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovascular hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury. Curr Neurovasc Res 2016; 13 (2): 135–46. 84. Sir A, D'Souza RF, Uguz S et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66 (10): 1312–20. 85. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2013. 86. Stahl SM. Stahl's essential psychopharmacology: Case studies. Cambridge university press, 2015. 87. Sullivan M, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain Med 2009; 10 (5): 806–12. 88. Ter Horst PG, Larmene-Beld KH, Bosman J et al. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J Clin Pharm Ther 2014; 39 (5): 541–4. 89. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997; 58 (9): 393–8. 90. Thase ME. Treatment of anxiety disorders with venlafaxine XR. Expert Rev Neurother 2006; 6 (3): 269–82. 91. Trouvin AP, Perrot S, Lloret-Linares C. Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment. Clin Ther 2017; 39 (6): 1104–22. 92. Troy SM, Parker VD, Hicks DR et al. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol 1996; 36 (2): 175–81. 93. Van Baardewijk M, Vis PM, Einarson TR. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin 2005; 21 (8): 1271–9. 94. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005; 39 (11): 1798–807. 95. Westin AA, Brekke M, Molden E et al. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. PLoS One 2017; 12 (7): e0181082. 96. Zarinara AR, Mohammadi MR, Hazrati N et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol 2010; 25 (7–8): 530–5. 97. Zissis NP, Harmoussi S, Vlaikidis N et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007; 27 (4): 315–24.